UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Open public recruiting
Unique ID issued by UMIN UMIN000019345
Receipt No. R000022270
Scientific Title Phase 1 Dose-escalation, Safety / Tolerability and Preliminary Efficacy Study of Intratumoral and Subcutaneous Administration of GEN0101 in Patients with Chemotheapy-resistant Malignant Pleural Mesothelioma (Phase I).
Date of disclosure of the study information 2015/10/15
Last modified on 2015/10/14

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Phase 1 Dose-escalation, Safety / Tolerability and Preliminary Efficacy Study of Intratumoral and Subcutaneous Administration of GEN0101 in Patients with Chemotheapy-resistant Malignant Pleural Mesothelioma (Phase I).
Acronym Phase 1 study of GeN0101 in patients suffering from Chemotheapy-resistant Malignant Pleural Mesothelioma
Scientific Title Phase 1 Dose-escalation, Safety / Tolerability and Preliminary Efficacy Study of Intratumoral and Subcutaneous Administration of GEN0101 in Patients with Chemotheapy-resistant Malignant Pleural Mesothelioma (Phase I).
Scientific Title:Acronym Phase 1 study of GeN0101 in patients suffering from Chemotheapy-resistant Malignant Pleural Mesothelioma
Region
Japan

Condition
Condition Chemotheapy-resistant Malignant Pleural Mesothelioma
Classification by specialty
Chest surgery
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 Primary endopoint:To determine the recommended dosage foe the phase 2 study through the assessment of DLT(Dose Limiting Toxicity)

Secondary endopoint: to evaluate the preliminary efficacy
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1 Others
Trial characteristics_2
Developmental phase Phase I

Assessment
Primary outcomes Assessment of DLT
Key secondary outcomes 1)Effect of tumor shirinkage
- RECIST
- Tumor marker (SMRP, CYFRA)
2)Induction of antitumor immunity
- NK cell
- IL-6
- IFN-gammma
3)Blood concentration of GEN0101/HVJ-E

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 GEN0101 will be administered four times per two weeks and then washed out for two weeks. This one cycle will be repeated twice. GEN0101 will be given at a dose of 30,000mNAU for each injection. If dose-escalation is permitted by independent data monitoring committee, another cohort will be given at a dose of 60,000mNAU for each injection.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
85 years-old >=
Gender Male and Female
Key inclusion criteria 1) Patients providing a written informed consent by voluntary agreement.
2) Age 20 =< and =<85 years old at the time of informed consent
3) Have a diagnosis of malignant pleural mesothelioma as confirmed by histology
4) Patinets suffering from chemoresistant malignant pleural mesothelioma, or patients without consecutive chemotherapy.
- More than 6 week between the end date of the Chemotherapy and the registration date when the Chemotherapy has been ineffective
5) PaO2 >=70 mmHg and SpO2>=93%
6) Expected survival period is more than 8 weeks after planned start date of investigational product
7) ECOG Performance Status 0 or 1
8) Patients with lesions which can be detected by diagnostic imaging such as MRI or CT scan prior to treatment, and which can be administered with GEN0101/HVJE
9) The marrow function, liver function and the kidney function must be kept as follows at the screening visit
(1) leukocyte >= 3,000/mcL
(2) neutrophil >=1,500/mcL
(3) platelet >=75,000/mcL
(4) hemoglobin >=8.0 g/dL.
(5) AST =<100 IU/L
(6) ALT =<100 IU/L
(7) total bilirubin =<2.5 mg/dL
(8) serum creatinine =<2.5 mg/dL
Key exclusion criteria 1) Have multiple brain metastases
2) Positive result of the prick test of GEN0101
3) Have serious complications such as uncontrolled active infection
4) Received systemic chemotherapy, radiotherapy or immunotherapy within 6 weeks before planned registration date
5) Received another investigational product within 4 weeks before the informed concent
6) Had a history of othr malignancy, except for the relapse-free and metastasis-free for more than 5 years after the last treatment at the registration
7) Have a interstitial pneumonia or fibrosing disease of the lung that need treatment
8) Have an active autoimmune disease
9)Receiving systemic administration of glucocorticosteroid which restrains immunity response.
10) Had a history of the autologous or homogeneous organ or tissue transplantation (Receiving immunosuppressive medication)
11) PT(%) less than 10% of the lower limit of normal or APTT more than 1.5 times of the upper limit of normal of local reference range at the screening visit
12) Pregnant or lactating women, except for the woman who discontinue to lactate (from the day of a written informed consent to the day after 30days of discontinue the administration)
In the case of womane, to conduct beta-HCG tests to confirm the presenceor absence of pregnancy
13) Positive result of the hepatitis B surface antigen, HCV antibody or HIV test at the screening visit
14) Inappropriate to be enrolled in this study judged by the investigators
Target sample size 12

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Meinoshin Okumura
Organization Osaka University Hospital
Division name Center for respiratory
Zip code
Address 2-15 Yamadaoka, Suita-shi, Osaka 565-0871, Japan
TEL 06-6879-3152
Email meinosin@thoracic.med.osaka-u.ac.jp

Public contact
Name of contact person
1st name
Middle name
Last name Katsuhisa Saito
Organization Osaka University Hospital
Division name Medical Center for Translational and Clinical Research
Zip code
Address 2-2 Yamadaoka, Suita-shi, Osaka 565-0871, Japan
TEL 06-6210-8289
Homepage URL
Email saitokt@dmi.med.osaka-u.ac.jp

Sponsor
Institute Osaka University Hospital, Center for respiratory
Institute
Department

Funding Source
Organization Japan Agency for Medical Research and Development
Organization
Division
Category of Funding Organization Other
Nationality of Funding Organization

Other related organizations
Co-sponsor GenomIdea,Inc.
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2015 Year 10 Month 15 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Open public recruiting
Date of protocol fixation
2015 Year 09 Month 17 Day
Date of IRB
Anticipated trial start date
2015 Year 11 Month 15 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2015 Year 10 Month 14 Day
Last modified on
2015 Year 10 Month 14 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000022270

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.